Navigation Links
Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With MYDICAR® Enzyme Replacement Therapy in the Journal Circulation
Date:6/27/2011

LA JOLLA, Calif., June 27, 2011 /PRNewswire/ -- Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announces that the data from its completed Phase 2 CUPID clinical study of MYDICAR® for the treatment of advanced heart failure is being published today online in Circulation, an American Heart Association journal.

"I am very encouraged that our approach of restoring a critical enzyme that is depleted in advanced heart failure may lead to new treatment options for those patients that continue to decline despite the best standard drug and device therapies," said Mariell Jessup, M.D., Professor of Medicine at the University of Pennsylvania's School of Medicine, who was the principal investigator and lead author of the study.  "The clinical deterioration seen in the placebo patients receiving ongoing optimal standard therapy emphasizes the tremendous unmet medical need in people with advanced heart failure. Based on these results we are encouraged that MYDICAR may one day fill this need."  

The previously announced top line results of 39 patients met its primary safety and efficacy endpoints at 6 months for high dose MYDICAR versus placebo.  Additionally, 12 months after receiving a single infusion of MYDICAR, patients treated with the highest dose versus placebo had an 88 percent risk reduction (Hazard Ratio = 0.12, P=0.003) of major cardiovascular events such as:

  • Death
  • Need for left ventricular assist device (LVAD) or cardiac transplant
  • Episodes of worsening of heart failure
  • Number of heart failure-related hospitalizations

The mean duration of hospitalization in the MYDICAR high dose group during the 12-month period was 0.4 days per patient compared with 4.5 days per patient in the placebo group. This finding is especially noteworthy because heart failure i
'/>"/>

SOURCE Celladon Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
2. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
3. ShangPharma Corporation Named a Top Ten Chinese Outsourcing Enterprise
4. Fox Chase Cancer Center Signs Agreement with Life Technologies Corporation
5. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011
6. China Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2011 Financial Results
7. Biomerix Corporation Reaches European Distribution Agreement with Cellon S.A.
8. Designed by Kids, Built by Volunteers: Roche, New Jersey Community Development Corporation, and KaBOOM! Build New Playground in Just One Day for Paterson Public School Children
9. Geminus Corporation Named Recipient of Second Annual Netsmart Technologies Customer Innovation Award
10. Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy
11. DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Horovitz , Ph.D., from its board of directors effective on ... August 2003, and served as its chairman from June 2006 ... the Nominating and Corporate Governance and Audit Committees of the ... than a decade of dedicated service to GenVec, and its ...
(Date:10/19/2014)... The Latin American hardware encryption display market ... with analysis and forecast of revenue. This market was ... to reach $2,366.8 million by 2018, at a CAGR ... the TOC of the Latin American hardware encryption market ... provided. It also provides a glimpse of the segmentation ...
(Date:10/19/2014)... October 19, 2014 The Asia-Pacific Speech ... market in Asia-Pacific with analysis and forecast of revenue. ... in 2014 to $208 million by 2019, at a ... to 2019. , Browse through the TOC of the ... of the in-depth analysis provided. It also provides a ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4
... Million to $247 Million -, Third Quarter 2008 Highlights:, -- ... 2007 -- Total revenues without Osteocel of $62.5 million; up 62.3% ... -- Gross profit of $54.7 million; up 73.2% from the third quarter ... in the third quarter of 2007, -- GAAP loss per ...
... Alert Limited,(OTC Bulletin Board: DYMC) (the "Company") is ... medical cannabis-based,pharmaceutical products. Today the Company is pleased ... all of the assets of Cannex, a privately,owned ... political,activist Steven W. Kubby (http://www.kubby.com ). The ...
... At CHEST 2008, PARI,Respiratory Equipment will ... breath-enhanced nebulizers and their in-vitro,performance and delivery ... "Our goal in testing various breath-enhanced ... delivery rate to ensure patients,receive clinically effective ...
Cached Biology Technology:Nuvasive Reports Third Quarter 2008 Financial Results 2Nuvasive Reports Third Quarter 2008 Financial Results 3Nuvasive Reports Third Quarter 2008 Financial Results 4Nuvasive Reports Third Quarter 2008 Financial Results 5Nuvasive Reports Third Quarter 2008 Financial Results 6Nuvasive Reports Third Quarter 2008 Financial Results 7Nuvasive Reports Third Quarter 2008 Financial Results 8Nuvasive Reports Third Quarter 2008 Financial Results 9Nuvasive Reports Third Quarter 2008 Financial Results 10Nuvasive Reports Third Quarter 2008 Financial Results 11Nuvasive Reports Third Quarter 2008 Financial Results 12Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado 2Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado 3
(Date:10/15/2014)... Rosenstiel Award for Distinguished Work in Biomedical Science by ... of genomic instability and its implications for the immune ... to win the Rosenstiel Award; the first, Rod McKinnon, ... the Charles A. Janeway Professor of Pediatrics and Professor ... at the Howard Hughes Medical Institute at Boston Children,s ...
(Date:10/14/2014)... of years since T. rex took its ... scientists is breathing life back into dinosaurs using high-powered ... research has important implications for how dinosaurs used their ... sense of smell and cool their brains. , ... student Jason Bourke, lead author of the new study ...
(Date:10/14/2014)... High doses of fish oil supplements, rich in omega-3 fatty ... irregular heartbeat in which the heart can beat as fast ... trial led by the Montreal Heart Institute were published in ... on October 7th. , For the trial, 337 patients with ... to 4 grams of fish oil a day or to ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... The Academy of Natural Sciences is the recipient of ... energy and for its renewable energy policy. The ... leadership role of the Academy,s Center for Environmental Policy ... collaboration of local organizations with the common goal of ...
... Washington, DC -- The 35th Annual Symposium on ... keynote speaker Dr. Francis S. Collins, Director of ... of more than two thousand professionals who are ... informatics, public health informatics, and consumer health informatics. ...
... coastal waters could compromise the ability of oysters and ... according to a new study led by University of ... the November 2011 issue of Nature Geoscience . ... carried by the Mississippi River to the northern Gulf ...
Cached Biology News:Informatics professionals meet in DC at AMIA's 35th Annual Symposium 2Informatics professionals meet in DC at AMIA's 35th Annual Symposium 3Informatics professionals meet in DC at AMIA's 35th Annual Symposium 4Run-off, emissions deliver double whammy to coastal marine creatures, UGA study finds 2
... using PULSin may be superior to transfection ... traditional transfection, with PULSin you can study ... time course of proteins in cells. Likewise, ... information than traditional RNA interference experiments. ...
... an automated instrument with a thin silicon ... using light or fluorescence microscopy. Biaxial strain ... fibroblast cells can be simulated by mechanical ... Y axis of our strain chamber. Strain ...
... The versatile ST-195 allows real-time observations ... conditions. This instrument has 64 different strain ... CO2 incubator. The thin silicon strain chamber ... inverted microscopes and fluorescence microscopy. ST-195 can ...
Immunogen GST fusion protein corresponding to full-length rat JNK3/ SAPK1b. Quality Assurance Routinely evaluated by immunoblot. Stability 2 years at -20°C from date of shipment GenBank A...
Biology Products: